ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD20 Bispecific Antibody DR-0201

Also written as “SAR448501” and “DR-0201”.

In Sanofi’s pipeline, CD20 bispecific mAb. Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, B-Cell, led by 2 companies.

Furthest: phase 1, since Apr 23, 20243 company-led studies, 2 open or runningNext primary completion: Jan 21, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi22 open or runningphase 1since Apr 23, 2024Apr 23, 2024Jan 21, 2028phase 1 · NCT06392477
Dren Bio10 open or runningphase 1since Aug 14, 2023Aug 14, 2023none ahead
  • Named in Sanofi’s own pipeline as SAR448501, phase 1, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2023First study: phase 1 study in Healthy Adult VolunteersNew to Dren BioDren Bio · NCT06008652 · 10 enrolled · Australia
  2. Apr 23, 2024Sanofi’s first study: phase 1 study in Lymphoma, B-CellNew to SanofiSanofi · NCT06392477 · 96 planned · Australia, Serbia, Singapore and more
  3. Oct 16, 2024Phase 1 study in Lupus Erythematosus, SystemicSanofi · NCT06647069 · 62 planned · Australia, Bosnia and Herzegovina, Georgia and more

Ahead

  1. Jan 21, 2028Primary completion: phase 1 study in Lymphoma, B-CellSanofi · NCT06392477
  2. Jun 25, 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicSanofi · NCT06647069

TargetBeta

“CD20 bispecific mAb”the company's pipeline, read by Claude · source
“A bispecific monoclonal antibody that targets the human tumor-associated antigen (TAA) CD20, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20 bispecific antibody DR-0201 targets and binds to CD20 on B-cell surface. This results in CD20-mediated signali…”NCIt, read by Claude

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06647069Lupus Erythematosus, Systemic · Australia, Bosnia and Herzegovina, Georgia and more1RecruitingSanofiJun 25, 202962
NCT06392477Lymphoma, B-Cell · Australia, Serbia, Singapore and more1RecruitingSanofiJan 21, 202896
NCT06008652Healthy Adult Volunteers · Australia1CompletedDren BioJul 24, 202410

How it is read

Names in the registry

  • “SAR448501”, 2 entries
  • “DR-0201”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.